BACKGROUND & AIMS: Technical advances have led to stool DNA (sDNA) tests that might accurately detect neoplasms on both sides of the colorectum. We assessed colorectal neoplasm detection by a next-generation sDNA test and effects of covariates on test performance. METHODS: We performed a blinded, multicenter, case-control study using archived stool samples collected in preservative buffer from 252 patients with colorectal cancer (CRC), 133 with adenomas ≥ 1 cm, and 293 individuals with normal colonoscopy results (controls); two-thirds were randomly assigned to a training set and one-third to a test set. The sDNA test detects 4 methylated genes, a mutant form of KRAS, and the α-actin gene (as a reference value) using quantitative, allele-specific, real-time target and signal amplification; it also quantifies hemoglobin. We used a logistical model to analyze data. RESULTS: The sDNA test identified 85% of patients with CRC and 54% of patients with adenomas ≥1 cm with 90% specificity. The test had a high rate of detection for all nonmetastatic stages of CRC (aggregate 87% detection rate for CRC stages I-III). Detection rates increased with adenoma size: 54% ≥ 1 cm, 63% >1 cm, 77% >2 cm, 86% >3 cm, and 92% >4 cm (P < .0001). Based on receiver operating characteristic analysis, the rate of CRC detection was slightly greater for the training than the test set (P = .04), whereas the rate of adenoma detection was comparable between sets. Sensitivities for detection of CRC and adenoma did not differ with lesion site. CONCLUSIONS: Early-stage CRC and large adenomas can be detected throughout the colorectum and with high levels of accuracy by the sDNA test. Neoplasm size, but not anatomical site, affected detection rates. Further studies are needed to validate the findings in a larger population and optimize the sDNA test.
RCT Entities:
BACKGROUND & AIMS: Technical advances have led to stool DNA (sDNA) tests that might accurately detect neoplasms on both sides of the colorectum. We assessed colorectal neoplasm detection by a next-generation sDNA test and effects of covariates on test performance. METHODS: We performed a blinded, multicenter, case-control study using archived stool samples collected in preservative buffer from 252 patients with colorectal cancer (CRC), 133 with adenomas ≥ 1 cm, and 293 individuals with normal colonoscopy results (controls); two-thirds were randomly assigned to a training set and one-third to a test set. The sDNA test detects 4 methylated genes, a mutant form of KRAS, and the α-actin gene (as a reference value) using quantitative, allele-specific, real-time target and signal amplification; it also quantifies hemoglobin. We used a logistical model to analyze data. RESULTS: The sDNA test identified 85% of patients with CRC and 54% of patients with adenomas ≥1 cm with 90% specificity. The test had a high rate of detection for all nonmetastatic stages of CRC (aggregate 87% detection rate for CRC stages I-III). Detection rates increased with adenoma size: 54% ≥ 1 cm, 63% >1 cm, 77% >2 cm, 86% >3 cm, and 92% >4 cm (P < .0001). Based on receiver operating characteristic analysis, the rate of CRC detection was slightly greater for the training than the test set (P = .04), whereas the rate of adenoma detection was comparable between sets. Sensitivities for detection of CRC and adenoma did not differ with lesion site. CONCLUSIONS: Early-stage CRC and large adenomas can be detected throughout the colorectum and with high levels of accuracy by the sDNA test. Neoplasm size, but not anatomical site, affected detection rates. Further studies are needed to validate the findings in a larger population and optimize the sDNA test.
Authors: D A Ahlquist; J E Skoletsky; K A Boynton; J J Harrington; D W Mahoney; W E Pierceall; S N Thibodeau; A P Shuber Journal: Gastroenterology Date: 2000-11 Impact factor: 22.682
Authors: Gavin C Harewood; Joseph P McConnell; Jonathan J Harrington; Douglas W Mahoney; David A Ahlquist Journal: Mayo Clin Proc Date: 2002-01 Impact factor: 7.616
Authors: Franka Loeve; Rob Boer; Ann G Zauber; Marjolein Van Ballegooijen; Gerrit J Van Oortmarssen; Sidney J Winawer; J Dik F Habbema Journal: Int J Cancer Date: 2004-09-10 Impact factor: 7.396
Authors: Stefan Harmsen; Stephan Rogalla; Ruimin Huang; Massimiliano Spaliviero; Volker Neuschmelting; Yoku Hayakawa; Yoomi Lee; Yagnesh Tailor; Ricardo Toledo-Crow; Jeon Woong Kang; Jason M Samii; Hazem Karabeber; Ryan M Davis; Julie R White; Matt van de Rijn; Sanjiv S Gambhir; Christopher H Contag; Timothy C Wang; Moritz F Kircher Journal: ACS Nano Date: 2019-02-04 Impact factor: 15.881
Authors: Theodore R Levin; Douglas A Corley; Christopher D Jensen; Amy R Marks; Wei K Zhao; Alexis M Zebrowski; Virginia P Quinn; Lawrence W Browne; William R Taylor; David A Ahlquist; Graham P Lidgard; Barry M Berger Journal: Dig Dis Sci Date: 2017-01-02 Impact factor: 3.199
Authors: Dennis Yang; Shauna L Hillman; Ann M Harris; Pamela S Sinicrope; Mary E Devens; David A Ahlquist Journal: World J Gastroenterol Date: 2014-05-07 Impact factor: 5.742